Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
SHEZF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $5 | $5 | $7 | $6 |
| % Growth | -3% | -23.9% | 12.5% | – |
| Cost of Goods Sold | $4 | $5 | $5 | $4 |
| Gross Profit | $2 | $1 | $2 | $2 |
| % Margin | 33.3% | 17.4% | 32.6% | 31.9% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $1 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $1 | $0 |
| Other Operating Expenses | $0 | $1 | -$0 | $0 |
| Operating Expenses | $1 | $2 | $1 | $1 |
| Operating Income | $1 | -$1 | $1 | $0 |
| % Margin | 14% | -15.8% | 11.6% | 3.6% |
| Other Income/Exp. Net | -$0 | -$0 | $0 | -$0 |
| Pre-Tax Income | $1 | -$1 | $1 | $0 |
| Tax Expense | $0 | -$0 | $0 | -$0 |
| Net Income | $1 | -$1 | $1 | $0 |
| % Margin | 12.2% | -14.4% | 10.2% | 3.8% |
| EPS | 0.44 | -0.53 | 0.5 | 0.16 |
| % Growth | 183% | -206% | 212.5% | – |
| EPS Diluted | 0.44 | -0.53 | 0.5 | 0.16 |
| Weighted Avg Shares Out | 1 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 1 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $1 | -$0 | $1 | $1 |
| % Margin | 22.7% | -5.9% | 19.3% | 11.5% |